The annual J.P. Morgan Healthcare Conference kicked off on Jan. 7, 2019 in San Francisco and healthcare investors are closely listening to presentaions by executives leading the world's most powerful drug and biotech companies.
More than 450 companies will be presenting, including Celgene (NASDAQ:CELG), Gilead Sciences (NASDAQ:GILD), and Teladoc (NYSE:TDOC) to more than 9,000 attendees. The Motley Fool's healthcare team will keep you informed about the most important announcements and offer our expert analysis. Check back daily for updates!
- All the Pre-JPM News Healthcare Investors Need to Know
- Should Celgene Investors Take Bristol's Money and Run?
- Why the Bristol-Myers Squibb Acquisition Is a Bad Deal for Celgene
- Here’s What Celgene Shareholders Are Getting From Bristol-Myers Squibb
- Here’s What Bristol-Myers Squibb Will Look Like After Acquiring Celgene
- 3 Things Pfizer's New CEO Just Said That Investors Will be Glad to Hear
- 3 Things Bristol-Myers Squibb Understands About Celgene That the Market Hasn't
- Why Sage Therapeutics Is Skyrocketing Today
- Here's Why Diplomat Pharmacy Slipped 10.5% on Monday
- Here's Why DexCom Traded 11.8% Higher Today
- 7 Things to Expect for Gilead Sciences in 2019
- 5 Things to Expect for Vertex Pharmaceuticals in 2019
- Here's Why Nektar Therapeutics Surged Today
- Is Eli Lilly Overpaying for Loxo Oncology?
- Why Eli Lilly Is Buying Loxo Oncology for $8 Billion
- Why Investors Didn't Like Illumina's JP Morgan Presentation -- but Should Have
- 3 Reasons Why CVS Health Thinks Its $78 Billion Bet Can Make You a Lot of Money
- 3 Things Alnylam's Management Wants You to Know
- 7 Reasons Why GW Pharmaceuticals' Epidiolex Will be a Big Winner
- Does Eli Lilly's $8 Billion Splurge Make Array BioPharma a Buy Now?
- 3 Big Reasons Why AbbVie Isn't Worried About Humira
- 4 Reasons Editas Medicine's Future Looks Really Bright
- What Intuitive Surgical Just Said About Its Future
- For Esperion Therapeutics, 2019 Could Be a Big Year
- Intuitive Surgical Is Playing Moneyball -- and Investors Will be the Big Winners
- 3 Biggest Stories at the J.P. Morgan Healthcare Conference This Year
- 3 Best-Performing Biotech Stocks at #JPM19
P.S. If you're interested in checking out how much things have changed since this time in 2018, here's last year's landing page.
The Motley Fool owns shares of and recommends Celgene, Gilead Sciences, and Teladoc Health. The Motley Fool has a disclosure policy.